SMMT vs. CRNX, BHVN, AXSM, INSM, RARE, PBH, HCM, ALKS, PRGO, and XENE
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Crinetics Pharmaceuticals (CRNX), Biohaven (BHVN), Axsome Therapeutics (AXSM), Insmed (INSM), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Alkermes (ALKS), Perrigo (PRGO), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Summit Therapeutics (NASDAQ:SMMT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.
In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 9 mentions for Summit Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.76 beat Summit Therapeutics' score of 0.70 indicating that Summit Therapeutics is being referred to more favorably in the news media.
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 7.0% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 83.7% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -4,223.27%. Summit Therapeutics' return on equity of -52.93% beat Crinetics Pharmaceuticals' return on equity.
Crinetics Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Crinetics Pharmaceuticals currently has a consensus target price of $57.58, suggesting a potential upside of 13.15%. Summit Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 51.21%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Crinetics Pharmaceuticals.
Summit Therapeutics received 149 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 66.34% of users gave Crinetics Pharmaceuticals an outperform vote while only 57.00% of users gave Summit Therapeutics an outperform vote.
Crinetics Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500.
Summary
Crinetics Pharmaceuticals beats Summit Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
